Welcome to our dedicated page for Sonnet Biotherapeutc Hldng SEC filings (Ticker: SONN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Struggling to decode immuno-oncology jargon buried in Sonnet BioTherapeutics Holdings Inc (SONN) disclosures? Each 10-K details FHAB platform breakthroughs, trial costs, and cash runway鈥攜et stretches over 200 pages. Problem: extracting what really matters before the next data readout or capital raise takes hours.
Solution: Stock Titan鈥檚 AI lifts the fog around Sonnet BioTherapeutics SEC filings explained simply. Our engine delivers plain-English highlights the moment a document hits EDGAR, whether it鈥檚 a Sonnet BioTherapeutics quarterly earnings report 10-Q filing spelling out liquidity, or an Sonnet BioTherapeutics 8-K material events explained alerting you to new trial initiations. Need to monitor insider sentiment? Get instant pings on Sonnet BioTherapeutics Form 4 insider transactions real-time and drill into every Sonnet BioTherapeutics executive stock transactions Form 4鈥攏o more manual searches.
Our coverage spans every form: the Sonnet BioTherapeutics annual report 10-K simplified for R&D spend trends, Sonnet BioTherapeutics proxy statement executive compensation to see how milestones drive pay, plus S-1, 424B, and Section 16 filings. AI-powered summaries spotlight cash burn trajectories, FHAB patent updates, and pivotal trial endpoints, turning dense biotech language into actionable insights.
Whether you鈥檙e investigating Sonnet BioTherapeutics insider trading Form 4 transactions ahead of catalyst dates, running a Sonnet BioTherapeutics earnings report filing analysis, or simply understanding Sonnet BioTherapeutics SEC documents with AI, our real-time dashboard keeps you a step ahead鈥攚ithout wading through PDFs.
WEC Energy Group (NYSE: WEC) filed a Form 144 indicating a proposed sale of 2,500 common shares (鈮�0.0008 % of the 321.9 million shares outstanding) through Morgan Stanley Smith Barney. The shares, valued at $276,362.50 based on market price, were acquired on 08/01/2025 via the exercise of employee stock options under a registered plan and are scheduled to be sold on or after 08/01/2025 on the NYSE. No other sales were reported in the past three months. The filer certifies there is no undisclosed material adverse information about WEC.
Rezolve AI plc (RZLV) completed a $50 million private investment in public equity (PIPE) on 25 July 2025, issuing 20 million ordinary shares at $2.50 each under Reg D and 搂4(a)(2) exemptions.
A.G.P./Alliance Global Partners acted as placement agent, entitled to a 7.0 % cash fee (partly offset by a 3.5 % credit tied to specific purchasers) and up to $130 k in reimbursable expenses. Net proceeds will fund working capital, potential accretive M&A and general corporate needs.
Investors received robust registration rights: Rezolve must file a resale registration statement within 7 days of closing and achieve effectiveness within 30 days (60 days if fully reviewed). The company is barred from announcing or issuing additional equity for 60 days post-effectiveness, with limited carve-outs. Key agreements鈥攊ncluding the Purchase Agreement, Placement Agent Agreement and Registration Rights Agreement鈥攁re filed as Exhibits 10.1-10.3.
Intellia Therapeutics, Inc. (NTLA) 鈥� Form 4 insider filing
EVP & CFO Edward J. Dulac III executed an automatic, non-volitional sale of 7,462 common shares on 23 Jul 2025 at $14.02 per share. The disposition was a mandatory 鈥渟ell-to-cover鈥� to satisfy federal and state tax-withholding obligations triggered by the vesting of RSUs on 22 Jul 2025.
Post-transaction, Dulac directly owns 106,062 NTLA shares; no indirect holdings or derivative security changes were reported. No options were exercised or granted, and the filing does not disclose any additional share sales or purchases.
The event does not materially alter management鈥檚 economic exposure to the company and should be viewed as administrative rather than discretionary trading activity.
FAQ
What is the current stock price of Sonnet Biotherapeutc Hldng (SONN)?
What is the market cap of Sonnet Biotherapeutc Hldng (SONN)?
What is the core focus of Sonnet BioTherapeutics Holdings Inc?
How does the company generate its therapeutic candidates?
What distinguishes Sonnet BioTherapeutics from other biotechnology companies?
In which therapeutic areas does the company have a presence?
What is FHAB technology and why is it important?
How should investors view the company's competitive position?
